PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1462937
PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1462937
Allogeneic Stem Cell Transplantation Market size was valued at USD 3,833.34 Million in 2023, expanding at a CAGR of 7.8% from 2024 to 2032.
Allogeneic stem cell transplantation involves the transfer of healthy stem cells from a genetically compatible donor to the patient, replacing damaged cells. This established therapeutic technique is used to address various hematological cancers, blood disorders, and immunological conditions. Stem cells for allogeneic transplants can be sourced from peripheral blood, bone marrow, umbilical cord blood, or adipose tissue. The field has witnessed significant progress in harvesting methods, expansion protocols, cryopreservation, and cell processing.
Allogeneic Stem Cell Transplantation Market- Market Dynamics
Rising prevalence of hematologic malignancies and non-malignant disorders to propel market demand
The Allogeneic Stem Cell Transplantation Market is expected to witness substantial growth driven by the rising prevalence of hematologic malignancies and non-malignant disorders, where this transplantation method has shown promise. Additionally, increased investments in research and development, along with a robust pipeline of stem cell therapies, are anticipated to propel market expansion. The rising number of clinical trials exploring allogeneic stem cell transplantation across various therapeutic areas bodes well for future market growth. The increasing incidence of chronic diseases like cancer, autoimmune disorders, and blood ailments is a key driver for the allogeneic stem cell transplantation market. Cases of diseases such as leukemia, multiple myeloma, and lymphoma have steadily risen over the past decade. Allogeneic hematopoietic stem cell transplantation offers a potentially curative approach for many of these high-risk and drug-resistant hematological malignancies. According to the World Health Organization (WHO), cancer caused nearly 10 million deaths worldwide in 2020. The growing pool of patients and demand for advanced therapies to address these conditions will fuel market growth. Numerous research studies and clinical trials are underway to assess the safety and efficacy of allogeneic stem cell therapies for new applications beyond traditional blood cancers and disorders. Several phase 2 and 3 trials are investigating allogeneic stem cell therapies for conditions such as bone marrow fibrosis, osteoarthritis, stroke, traumatic brain injury, and myocarditis, among others. Robust pipeline activities aimed at expanding the treatment landscape will open up new avenues for market growth. For example, Novartis, a global pharmaceutical company, has initiated a phase 2 clinical trial using allogeneic stem cell transplantation to treat bone marrow fibrosis, with an expected completion date of October 2024.
Allogeneic Stem Cell Transplantation Market- Key Insights
As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 7.8% over the forecast period (2024-2032)
Based on Source segmentation, Bone Marrow was predicted to show maximum market share in the year 2023
Based on End User segmentation, Hospitals was the leading type in 2023
On the basis of region, North America was the leading revenue generator in 2023
The Global Allogeneic Stem Cell Transplantation Market is segmented on the basis of Cell Type, Source, Application, End User, and Region.
The market is divided into two categories based on Source: Bone Marrow, Peripheral Blood, Umbilical Cord Blood, Adipose Tissue, Dental Pulp, and Others. The bone marrow allogeneic stem cell transplantation market is poised to command a significant global market share in 2023. Bone marrow stem cell transplantation emerges as a promising therapeutic avenue for select hematological disorders, particularly in cases where conventional treatments have proven ineffective or disease recurrence has transpired. For eligible individuals, this treatment modality holds paramount importance as it offers the potential to extend life expectancy significantly, often free from relapse.
The market is divided into three categories based on End User: Hospitals, Research Institutes, Specialty Clinics, and Others. In 2023, the hospital end user segment predominantly contributes to allogeneic stem cell transplantation services, primarily owing to the sophisticated medical infrastructure available within modern hospitals. Notably, contemporary hospitals are equipped with cutting-edge medical technologies, including specialized units dedicated to bone marrow transplantation. These resources empower hospitals to deliver comprehensive pre- and post-transplant care to hematopoietic stem cell transplant (HSCT) recipients, particularly in regions such as the United States, Germany, the United Kingdom, China, and India.
Allogeneic Stem Cell Transplantation Market- Geographical Insights
Geographically, this market is widespread into the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These regions are further divided as per the nations bringing business.
Companies and healthcare institutions are implementing strategic measures to enhance patient outcomes, foster innovation, and enhance access to transplantation services. A crucial aspect of this strategy involves continual advancements in transplant technologies and protocols through dedicated research and development endeavors. This encompasses investments in innovative prophylaxis methods for graft-versus-host disease (GVHD), refinement of conditioning regimens, and exploration of alternative stem cell sources to broaden eligibility criteria and enhance transplant success rates. Collaborations with academic institutions and research organizations play a vital role in validating and optimizing these advancements, ensuring their clinical applicability and effectiveness.
In September 2023, MaaT Pharma, a biotechnology company based in France, announced that the European Medicines Agency (EMA) has granted orphan drug designation to MaaT033. Developed by MaaT Pharma, MaaT033 is an adjunctive and maintenance therapy aimed at improving overall survival in Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT).
GLOBAL ALLOGENEIC STEM CELL TRANSPLANTATION MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHT
Celgene Corporation
Mesoblast Ltd.
Pluristem Therapeutics Inc.
MEDIPOST Co., Ltd.
Osiris Therapeutics, Inc.
Cynata Therapeutics Limited
Takeda Pharmaceutical Company Limited
Astellas Pharma Inc.
Cellular Biomedicine Group, Inc.
Biosolution Co., Ltd.
StemCell Technologies Inc.
Caladrius Biosciences, Inc.
ViaCord
Vericel Corporation
Regen Biopharma Inc.
Gamida Cell Ltd.
Histogenics Corporation
BrainStorm Cell Therapeutics Inc.
Lineage Cell Therapeutics, Inc.
Others